Compare Novavax Inc (NVAX) vs United Parcel Service Inc (UPS) Price & Performance

Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.

The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.

UPS trades at $100.48, down 1.78% on the day, with technical indicators showing bearish momentum as the stock tests key support levels. Fundamentally, the company maintains solid profitability with 5.08% net margin and 29.66% ROE, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. Recent strategic moves include a $2B+ global investment initiative and executive leadership restructuring announced in August 2026.

The stock presents a mixed outlook with attractive valuation (P/E 18.68, below industry average) and strong dividend yield, but faces headwinds from declining revenue trends and competitive pressures. Analyst consensus leans neutral with $117.90 price target suggesting 17% upside potential, though execution risks on the new operating model and dividend sustainability concerns warrant caution.